Comparison
Two synthetic GHRH analogues that both stimulate growth hormone release from the pituitary, but with substantially different half-lives, approval status, and intended populations. Tesamorelin is an FDA-approved drug; CJC-1295 is a research compound with flexible dosing options depending on whether the DAC modification is included.
Quick Answer
Tesamorelin is an FDA-approved GHRH analogue specifically indicated for HIV-associated lipodystrophy, with a short half-life requiring daily injection and a well-documented clinical trial base. CJC-1295 is a research-use GHRH analogue with a significantly longer half-life (especially with DAC modification), used for general GH axis stimulation, body composition, and anti-ageing goals. Tesamorelin has stronger regulatory standing and more human data; CJC-1295 offers more flexible dosing and broader application in research contexts.
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Compound class | GHRH analogue, GHRH 1-44 derivative | GHRH analogue, GHRH 1-29 derivative |
| Structural modification | Trans-3-hexenoic acid conjugated to N-terminus for DPP-IV resistance | No DAC: four amino acid substitutions for stability (also called mod GRF 1-29); with DAC: Drug Affinity Complex maleimide group for albumin binding and extended half-life |
| Half-life | Approximately 26 minutes | Without DAC: approximately 30 minutes; with DAC: approximately 8 days |
| Typical research dosing | 2 mg subcutaneous daily | Without DAC: 100 to 200 mcg, 2 to 3 times daily; with DAC: 2 mg once or twice weekly |
| FDA approval status | Approved (Egrifta) for HIV-associated lipodystrophy | Not FDA-approved for any indication; research use only |
| Human trial evidence | Multiple phase III RCTs; robust dataset in HIV lipodystrophy population | Limited; primarily pharmacokinetic and phase I data; no completed phase III trials |
| Primary target population | HIV-positive adults with antiretroviral-related lipodystrophy | General research contexts: body composition, GH axis optimisation, anti-ageing |
| IGF-1 elevation | Well-documented; elevates IGF-1 within normal physiological range at approved dose | Documented in pharmacokinetic studies; DAC version sustains IGF-1 elevation longer |
| Combination use | Rarely combined in research; used as standalone in its approved indication | Commonly combined with Ipamorelin for complementary GHRH and GHRP axis stimulation |
| Availability | Pharmaceutical grade via prescription; compounded forms exist but attract regulatory scrutiny | Research peptide market; not available as a pharmaceutical product |
Tesamorelin and CJC-1295 both belong to the GHRH analogue class: synthetic peptides designed to mimic the action of endogenous growth hormone-releasing hormone. Endogenous GHRH is a 44-amino acid hypothalamic peptide that binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. Both compounds preserve this core mechanism: receptor binding on somatotrophs, amplification of GH pulse amplitude, and downstream elevation of IGF-1.
Tesamorelin is based on the full-length GHRH sequence (residues 1-44) conjugated to a trans-3-hexenoic acid moiety at the N-terminus. This modification confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary enzymatic mechanism by which endogenous GHRH is inactivated in plasma. The result is a compound with GHRH-equivalent receptor activity and improved stability. Tesamorelin was developed by Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a metabolic complication of antiretroviral therapy.
CJC-1295 is based on GHRH(1-29), the minimally active fragment of GHRH that retains full receptor binding and GH-stimulating activity. The 1-29 fragment is also the basis of Sermorelin, the earliest GHRH analogue to reach clinical use. CJC-1295 exists in two distinct forms that differ substantially in pharmacokinetics. The non-DAC form (also called modified GRF 1-29 or mod GRF 1-29) incorporates four amino acid substitutions to improve stability and DPP-IV resistance without altering the half-life significantly. The DAC form adds a reactive maleimide group that covalently binds to albumin in plasma, extending the half-life from approximately 30 minutes to approximately 8 days.
The DAC modification changes CJC-1295's pharmacodynamic profile fundamentally. Instead of producing discrete GH pulses that mimic physiological pulsatility, CJC-1295 with DAC produces a sustained, blunted GH elevation across days. Whether this sustained elevation is preferable to pulsatile stimulation for body composition or anti-ageing goals is debated in research contexts, and the physiological implications of chronically elevated GH without normal pulsatility are not fully characterised.
With a plasma half-life of approximately 26 minutes, Tesamorelin requires once-daily subcutaneous injection at the approved dose of 2 mg. The short half-life means each injection produces a transient GH pulse rather than sustained elevation. This pulsatile pattern is physiologically similar to the natural rhythm of GHRH-driven GH secretion, where hypothalamic GHRH pulses drive discrete GH release events from the pituitary, followed by somatostatin-mediated suppression between pulses. The once-daily protocol makes Tesamorelin relatively convenient compared to short-acting GHRPs that require multiple daily injections.
CJC-1295 without DAC (mod GRF 1-29) has a half-life of approximately 30 minutes, similar to Tesamorelin. Used at 100 to 200 mcg per injection, it is typically administered 2 to 3 times daily, often timed with naturally occurring GH pulse windows such as morning, evening, and a pre-sleep injection. This dosing approach aims to amplify existing GH pulsatility rather than create continuous elevation, and is frequently combined with Ipamorelin to simultaneously stimulate the GHRP and GHRH axes for additive GH release.
CJC-1295 with DAC extends the half-life to approximately 8 days through albumin binding. At a typical research dose of 2 mg administered once or twice weekly, it sustains elevated GH and IGF-1 levels across the dosing interval. This reduces injection frequency significantly but changes the GH secretion pattern from pulsatile to tonic. Researchers use the DAC formulation when convenience and sustained IGF-1 elevation are priorities; the non-DAC formulation when physiological pulsatility is preferred.
Neither CJC-1295 formulation has a clinically validated dose derived from phase III trials. Research dosing is extrapolated from pharmacokinetic studies and observational use, which is a key limitation compared to Tesamorelin's well-characterised approved dose.
Tesamorelin is the only GHRH analogue to have received FDA approval. Its approval was supported by two pivotal phase III double-blind placebo-controlled trials (LIPO-010 and LIPO-011) in HIV-infected patients with excess abdominal fat, demonstrating statistically significant reductions in visceral adipose tissue measured by CT scan. The human evidence base for Tesamorelin in its approved indication is robust by research peptide standards, including long-term extension trial data and a well-characterised adverse effect profile.
Beyond its approved indication, Tesamorelin has been investigated for mild cognitive impairment in older adults (the TECC trial at Vanderbilt University), with preliminary findings suggesting potential cognitive benefits, though this indication is not approved. The existence of human phase III data across multiple indications distinguishes Tesamorelin sharply from CJC-1295 in terms of evidence quality.
CJC-1295's published human evidence consists primarily of pharmacokinetic studies. The original CJC-1295 paper (Ionescu and Frohman, 2006) demonstrated dose-dependent increases in GH and IGF-1 in healthy adults, with the DAC formulation showing GH elevation sustained for up to 6 days post-injection. This established the pharmacodynamic proof of concept but does not constitute the controlled trial evidence needed to validate clinical efficacy or establish optimal dosing for specific outcomes.
No phase III trials have been completed for CJC-1295 in any indication. Its use in research communities relies on mechanistic extrapolation from GHRH biology and observational data. This is a meaningful distinction: Tesamorelin's benefits and risks are characterised in controlled human populations; CJC-1295's are inferred from pharmacokinetics and GHRH class biology.
As GHRH analogues acting through the same receptor, Tesamorelin and CJC-1295 share a class-level side effect profile. Both can cause fluid retention (peripheral oedema), joint pain or stiffness (arthralgia), and at higher doses or in susceptible individuals, impairment of glucose metabolism. The GH axis elevations produced by both compounds can increase insulin resistance and fasting glucose, which is clinically relevant in populations with pre-existing insulin resistance, type 2 diabetes, or metabolic syndrome.
Tesamorelin's phase III data provide the most comprehensive human safety characterisation for a GHRH analogue. The trial data documented glucose metabolism effects including increased fasting glucose and HbA1c in some participants, injection site reactions, and peripheral oedema as primary adverse effects. Glucose metabolism effects were more pronounced in participants with pre-existing glucose impairment, making baseline glycaemic status relevant to risk assessment.
For CJC-1295, the safety data are substantially less detailed. The pharmacokinetic studies provide limited adverse effect information, and long-term safety in humans is not characterised. The DAC formulation's sustained GH elevation raises a theoretical concern about prolonged IGF-1 elevation and its implications for cell growth stimulation over extended periods, though this has not been formally evaluated in human trials.
Both compounds require monitoring of IGF-1 levels during use to avoid supraphysiological elevation. Both are contraindicated in active malignancy due to the growth-promoting effects of elevated GH and IGF-1. Neither should be used without medical supervision in populations with pre-existing metabolic disease.
For its approved indication (HIV-associated lipodystrophy), Tesamorelin is the evidence-based choice with no legitimate research compound alternative. Its phase III trial data, FDA approval, and well-characterised dosing make it appropriate for clinical application in this population. Researchers studying visceral adipose tissue reduction or IGF-1 modulation in a rigorous trial context will find Tesamorelin's known pharmacology more useful as an anchor.
For general GH axis stimulation research, body composition goals, or anti-ageing applications, CJC-1295 is more commonly used. The choice between the DAC and non-DAC formulations depends on whether pulsatile GH stimulation (non-DAC, combined with Ipamorelin for optimal pulsatility) or sustained IGF-1 elevation (DAC) is the research priority. The non-DAC form combined with Ipamorelin is among the most commonly described GH research protocols, with Ipamorelin providing the GHRP stimulus and CJC-1295 providing the GHRH stimulus simultaneously.
Combining Tesamorelin and CJC-1295 is not a documented research protocol, as both are GHRH receptor agonists and combining them would produce overlapping receptor mechanisms without the complementary benefit of pairing a GHRH analogue with a GHRP. The choice between them is typically driven by the research context: Tesamorelin for its approved indication or when documented human trial data are required; CJC-1295 for broader GH axis research where dosing flexibility and GHRP combinations are the priority.
Both are synthetic GHRH analogues that stimulate GH release by binding GHRH receptors on pituitary somatotrophs. Tesamorelin is based on GHRH(1-44) with a trans-3-hexenoic acid N-terminal modification, has a half-life of approximately 26 minutes, requires daily subcutaneous injection at 2 mg, and is FDA-approved for HIV-associated lipodystrophy with multiple phase III RCTs. CJC-1295 is based on GHRH(1-29) and comes in two formulations: without DAC (half-life approximately 30 minutes, dosed multiple times daily) and with DAC (half-life approximately 8 days, dosed weekly). CJC-1295 is a research compound with no FDA approval and limited human trial data.
For HIV-associated lipodystrophy, Tesamorelin has the superior evidence base with phase III RCT support and FDA approval. For general GH axis research, body composition, and anti-ageing applications, CJC-1295 is more commonly used due to dosing flexibility, compatibility with Ipamorelin combinations, and lower cost compared to pharmaceutical-grade Tesamorelin. Neither compound is better in an absolute sense; the appropriate choice depends on the research objective and regulatory context.
There is no documented research protocol for combining Tesamorelin and CJC-1295. Both are GHRH receptor agonists; combining two compounds with the same receptor mechanism would produce overlapping effects at the GHRH receptor without the complementary mechanism advantage of combining a GHRH analogue with a GHRP like Ipamorelin. Concurrent use is not a described research application and is not recommended.
Tesamorelin has substantially more human clinical research data, including two pivotal phase III RCTs, long-term extension trial data, and additional clinical investigations for cognitive impairment. CJC-1295 human evidence consists primarily of pharmacokinetic studies. Sermorelin, as the earliest GHRH analogue to reach clinical use, also has a substantial clinical literature, particularly in paediatric growth hormone deficiency.
CJC-1295 without DAC (also called modified GRF 1-29 or mod GRF 1-29) is GHRH(1-29) with amino acid substitutions for stability, retaining a half-life of approximately 30 minutes. It is dosed multiple times daily to produce discrete GH pulses. CJC-1295 with DAC adds a Drug Affinity Complex maleimide group that covalently binds to circulating albumin, extending the half-life to approximately 8 days and enabling once or twice weekly dosing. The DAC version produces a sustained, blunted GH elevation rather than pulsatile release. The two formulations are pharmacodynamically distinct and represent different research tools rather than interchangeable versions of the same compound.
Related Comparisons